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iAbstract
Background: The Epithelial-Mesenchymal Transition (EMT) endows epithelial-looking
cells with enhanced migratory ability during embryonic development and tissue repair.
EMT can also be co-opted by cancer cells to acquire metastatic potential and
drug-resistance. Recent research has argued that epithelial (E) cells can undergo
either a partial EMT to attain a hybrid epithelial/mesenchymal (E/M) phenotype
that typically displays collective migration, or a complete EMT to adopt a
mesenchymal (M) phenotype that shows individual migration. The core EMT
regulatory network - miR-34/SNAIL/miR-200/ZEB1 - has been identified by various
studies, but how this network regulates the transitions among the E, E/M, and M
phenotypes remains controversial. Two major mathematical models – ternary
chimera switch (TCS) and cascading bistable switches (CBS) - that both focus on
the miR-34/SNAIL/miR-200/ZEB1 network, have been proposed to elucidate the
EMT dynamics, but a detailed analysis of how well either or both of these two
models can capture recent experimental observations about EMT dynamics
remains to be done.
Results: Here, via an integrated experimental and theoretical approach, we first
show that both these two models can be used to understand the two-step
transition of EMT - E→E/M→M, the different responses of SNAIL and ZEB1 to
exogenous TGF-β and the irreversibility of complete EMT. Next, we present new
experimental results that tend to discriminate between these two models. We
show that ZEB1 is present at intermediate levels in the hybrid E/M H1975 cells,
and that in HMLE cells, overexpression of SNAIL is not sufficient to initiate EMT
in the absence of ZEB1 and FOXC2.
Conclusions: These experimental results argue in favor of the TCS model
proposing that miR-200/ZEB1 behaves as a three-way decision-making switch
enabling transitions among the E, hybrid E/M and M phenotypes.
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The Epithelial-to-Mesenchymal Transition (EMT) and its reverse process -
Mesenchymal-to-Epithelial Transition (MET) - play critical roles during embryonic
development and tissue repair. This process can also be utilized by cancer cells to ac-
quire properties similar to stem cells, to become drug-resistant and to obtain enhanced
migratory abilities (Nieto, 2013; Kalluri & Weinberg, 2009). Epithelial cells from a pri-
mary tumor can undergo EMT to lose cell-cell adhesion and acquire mesenchymal in-
vasive properties (Tsai & Yang, 2013). These transitioned cells can enter blood vessels
and migrate as Circulating Tumor Cells (CTCs) (Gupta & Massagué, 2006). Eventually, the
CTCs may exit the vasculature at a distant organ, undergo MET, seed and thereby form a
secondary tumor or metastases (Nieto, 2013), which are the cause of 90% of cancer-related
deaths (Gupta & Massagué, 2006). Hence decoding the operating principles of EMT is cru-
cial to unveil the mechanism of enhanced metastasis and therapeutic failure.
Emerging evidence shows that in addition to epithelial (E) and mesenchymal (M)
phenotypes, cells can acquire a hybrid epithelial/mesenchymal (E/M) phenotype (also
referred to as ‘partial EMT’) that has combined traits of epithelial (cell-cell adhesion)
and mesenchymal (invasion) phenotypes (Revenu & Gilmour, 2009; Micalizzi et al.,
2010; Friedl & Gilmour, 2009; Yu et al., 2013; Hou et al., 2011; Jolly et al., 2015; Bierie
et al., 2017). Consequently, cells in the hybrid E/M phenotype can migrate collectively
as a cluster (Boareto et al., 2016). These clusters, which originate from the primary tumor
front, can display up to 50 times higher tumor-formation potential as compared to indi-
vidually migratory mesenchymal cells (Aceto et al., 2014). In addition, the hybrid E/
M phenotype has been suggested to be more correlated with stem-like properties
(Jolly et al., 2014; Grosse-Wilde et al., 2015) and chemoresistance (Goldman et al.,
2015) as compared to epithelial and mesenchymal phenotypes. Thus characterizing
the hybrid E/M phenotype can contribute to a full understanding of the role of
EMT in metastasis and chemoresistance.
The signaling network orchestrating EMT is complex. For example, EMT can be
triggered by many signaling pathways such as TGF-β, Notch and Wnt (Thiery &
Sleeman, 2006), and different mechanical factors such as extracellular matrix dens-
ity (Kumar et al., 2014) and mechanical stress (Gomez et al., 2010). On the other
hand, EMT can be repressed by tumor suppressors such as p53 (Chang et al.,
2011), transcription factors such as GRHL2 (Cieply et al., 2013) and OVOL (Li &
Yang, 2014), and microRNA families such as miR-200 and miR-34 (Zaravinos &
Zaravinos, 2015). Despite the complexity of the signaling network, there appears to
exist a ‘hub’ that functions as the master regulator of EMT. This ‘hub’ consists of
two interconnected mutually inhibitory feedback loops between microRNAs and
transcription factors – one between the miR-34 family and SNAIL1/2, and the
other between the miR-200 family and ZEB1/2 (Siemens et al., 2011; Hill et al.,
2013; Brabletz & Brabletz, 2010). High levels of miR-200 and miR-34 are associated
with an epithelial phenotype, and high levels of ZEB1/2 and SNAIL are associated
with a mesenchymal phenotype (Siemens et al., 2011; Bracken et al., 2008; Park
et al., 2008; Somarelli et al., 2016).
Recently, two different mathematical models - the ternary chimera switch (TCS) (Lu et al.,
2013) and the cascading bistable switches (CBS) (Zhang et al., 2014) – have been proposed
to elucidate phenotypic transitions during EMT (Fig. 1a, b, see Additional file 1: SI Section
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Fig. 1 Schematic representations of the ternary chimera switch (TCS) and the cascading bistable switches
(CBS) models. The core EMT regulatory network in the TCS (a) model and the CBS (b) model. Bifurcation
diagrams of mesenchymal (M) marker levels in response to exogenous TGF-β in the TCS model (c) and the
CBS model (d). Bifurcation diagrams of ZEB1 mRNA levels in response to SNAIL for the miR-200/ZEB1 circuit
in the TCS model (e) and the CBS model (f). In (a) and (b), μ34 represents miR-34 and μ200 represents miR-200.
Solid arrows represent transcriptional activations and solid bar-headed arrows represent transcriptional
inhibitions. Dashed bar-headed arrows represent microRNA-mediated regulations. The circled arrow
along with ZEB1 in (a) represent ZEB1 self-activation and the circled bar-headed arrow along with SNAIL in (a)
and (b) represent SNAIL self-inhibition. In (c) and (d), blue solid lines represent stable states and red dotted lines
represent unstable states. The dotted arrow represents transitions between different stable states. The cell
phenotype corresponding to each stable state is labeled and also shown in cartoon
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regulatory circuits – miR-34/SNAIL and miR-200/ZEB (which will be referred to as miR-
200/ZEB1 hereafter since the experimental results discussed later focus on ZEB1),
and can explain the two-step transitions during EMT - E→E/M→M (Fig. 1c, d)
(Lu et al., 2013; Zhang et al., 2014). Despite these similarities, however, the TCS
and CBS models differ on an important aspect – the role of ZEB1 during EMT.
The TCS model proposes that ZEB1 levels are trimodally distributed among E, E/
M and M phenotypes, and intermediate levels of ZEB1 are required to maintain
the hybrid E/M phenotype (Lu et al., 2013). In other words, an upregulation of
ZEB1 levels is required to both initiate partial EMT (E→E/M) and complete EMT
(E/M→M) (Fig. 1e). In contrast, the CBS model proposes that ZEB1 levels are
bimodally distributed, such that the levels of ZEB1 in E and hybrid E/M phenotypes are
relatively low and not significantly different, while that in M phenotype are relatively high
(Zhang et al., 2014) (Fig. 1f). These differences in the proposed role of ZEB1 exist
between TCS and CBS models because of the different characterizations of the
EMT regulatory circuits by each model. The TCS model proposes the miR-200/
ZEB1 circuit to be the three-way decision-making switch of EMT and the miR-34/
SNAIL to be a monostable noise-buffering integrator (Lu et al., 2013). In contrast,
the CBS model proposes that both the miR-34/SNAIL circuit and the miR-200/
ZEB1 circuit are bistable switches, with miR-34/SNAIL responsible for the switch
from E to E/M and miR-200/ZEB1 responsible for the switch from E/M to M
(Zhang et al., 2014).
Jia et al. Cancer Convergence  (2017) 1:2 Page 4 of 19Despite modeling the same circuit, a key reason why these two models have different
predictions is that the TCS model, but not the CBS model, includes the self-activation
of ZEB1. It is in fact well-known that including self-activation in toggle switch systems
can lead to tristability (Huang et al., 2007; Zhou & Huang, 2011; Lu et al., 2013). In this
study, we first confirm the importance of the ZEB1 self-activation based on recently
published work on the self-enforcing CD44s/ZEB1 feedback loop. The trimodal distri-
bution of ZEB1 from the TCS modeling analysis is further supported by gene expres-
sion data from NCI-60 cell lines and the immunofluorescence (IF) results of the hybrid
E/M non-small cell lung cancer (NSCLC) cell line – H1975.
Next, we show that both the TCS model and the CBS model can recapitulate
currently published experimental results such as (a) EMT is a two-step transition – E
to hybrid E/M to M, (b) a lower TGF-β concentration is required for the activation of
SNAIL compared to that for ZEB1, (c) the transition from E to E/M is reversible while
the transition from E/M to M is largely irreversible in MCF10A cells. Hence, much of
the existing data does not distinguish between these two possibilities.
Hence, we present novel experimental data that is capable in principle of discriminating
between the two models. We show that overexpression of SNAIL in HMLE cells cannot
induce EMT without the expression of ZEB1 (and FOXC2, which is another important
mediator of EMT and is known to regulate ZEB1 (Mani et al., 2007). This observation
suggests that the miR-34/SNAIL circuit may not be responsible for the switch from E to
E/M phenotypes and is therefore more congruent with predictions from the TCS model.Results
The CD44s/ZEB1 feedback loop enables the miR-200/ZEB1 circuit to function as a
three-way switch
The TCS model incorporates a direct ZEB1 self-activation link based on the contribu-
tion of ZEB1 in stabilizing the SMAD complexes; this link can reinforce ZEB1 levels
that are raised via the TGF-β pathway (Hill et al., 2013). Here, we include in the model
recently published evidence regarding a self-reinforcing feedback loop of ZEB1 via
ESRP1 and CD44s (Preca et al., 2015) (Fig. 2a), and show that this feedback loop indeed
enables the tristability of the miR-200/ZEB1 circuit (see Additional file 1: SI Section 3
for the model formulation of the CD44s/ZEB1 feedback loop and Additional file 1:
Table S1 for relevant parameters).
CD44, a crucial stem cell marker, has two major isoforms – CD44s (the CD44 stand-
ard isoform) and CD44v (CD44 variant isoform) (Ponta et al., 2003). Whereas the total
amount of CD44 is maintained largely unchanged during EMT, the isoform switch
from CD44v to CD44s is essential for the progression of EMT (Brown et al., 2011;
Zhao et al., 2016), and CD44s can upregulate ZEB1 (Preca et al., 2015). This isoform
switch is regulated by a splicing factor - epithelial splicing regulatory protein 1 (ESRP1)
- which promotes the splicing of CD44v and inhibits that of CD44s (Brown et al.,
2011). The transcription of ESRP1 can be directly inhibited by ZEB1, and therefore
ZEB1 can upregulate itself by promoting the production of CD44s (Preca et al., 2015;
Brown et al., 2011).
To analyze the effect of the CD44s/ZEB1 feedback loop on the behavior of the miR-
200/ZEB1 circuit, we calculated a bifurcation diagram (Fig. 2a) to illustrate the
a b
d e
c
f
Fig. 2 The CD44s/ZEB1 feedback loop enables the miR-200/ZEB1 circuit to function as a three-way switch.
(a) Top panel: The SNAIL-driven miR-200/ZEB1 circuit including the CD44s/ZEB1 feedback loop. Bottom
panel: Bifurcation diagram of ZEB1 mRNA levels for the miR-200/ZEB circuit in response to SNAIL. (b) Top
panel: The S1-S2-driven miR-200/ZEB1 circuit including the CD44s/ZEB1 feedback loop. S1 represents a
transcriptional inhibition signal on miR-200 and S2 represents a transcriptional activation signal on ZEB1.
Bottom panel: The phase diagram (a two-parameter bifurcation) of the miR-200/ZEB1 circuit driven by
signals S1 and S2. In (a) and (b), the dotted bar-headed arrows represent the alternative splicing of CD44
mRNAs by ESRP1. Different colors in the bifurcation diagrams represent different co-existences of stable states.
For example, the blue colored region marks the tristable phase – {E, E/M, M}, where all three phenotypes - E, E/
M and M can be the stable states. In (b), the region marked by black dots in phase diagram represents
the parameter region of S1and S2 for the existence of the hybrid E/M phenotype – existing either alone -
{E/M} or in combination with other stable states – {E, E/M}, {M, E/M} and {E, E/M, M}. (c) Top panel: Relative gene
expression levels of ZEB1 and ESRP1 in epithelial (n = 11), hybrid E/M (n = 11) and mesenchymal (n = 37) cell
lines from NCI-60. Bottom panel: Pearson’s correlations between gene expression of ESRP1 and ZEB1, VIM,
CDH1 and OVOL2. ‘*’ represents P value ≤0.05. ‘**’ represents P value <0.005. ‘***’ represents P value <0.0001.
(d) Immunofluorescence images showing different expression patterns of EMT markers in NSCLC cell lines. In the
first column, blue is for DAPI, red is for ZEB1 and green is for CDH1. In the second column, blue is for DAPI, red is
for CDH1 and green is for VIM. (e) mRNA levels of CDH1, VIM, SNAIL and ZEB1 in NSCLC cell lines. (f) Protein levels
of CDH1, VIM, SNAIL, ZEB1 and FOXC2 in NSCLC cell lines. In (e) and (f), H820 and H1437 are epithelial cell lines,
H1299 and H2030 are mesenchymal cell lines, H1975 is hybrid E/M cell line and H1944 is a mixture of E and M cells
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back loop enables the miR-200/ZEB1 circuit to acquire three stable states (phenotypes)
– (low ZEB1, high ESRP1) corresponding to the E phenotype, (medium ZEB1, medium
ESRP1) corresponding to the hybrid E/M phenotype and (high ZEB1, low ESRP1)
corresponding to the M phenotype. The hybrid E/M phenotype is not seen upon re-
moval of the CD44s/ZEB1 feedback loop (Additional file 1: Figure S1), demonstrating
that self-activation in a toggle switch is critical for attaining more than two stable states
(Huang et al., 2007; Zhou & Huang, 2011; Lu et al., 2013). To understand the diverse
EMT-inducing results (e.g., by hypoxia, which can upregulate both SNAIL and ZEB1 or
by TGF-β, which mainly upregulates SNAIL), we calculated the phase diagram where
the miR-200/ZEB1 circuit is driven by two independent signals – a transcriptional
inhibition signal S1 on miR-200 and a transcriptional activation signal S2 on ZEB1 (Fig. 2b).
Different combinations of S1 and S2 allow 7 possible phases – 3 monostable phases - {E},
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M, M} (Fig. 2b). The bistable and tristable phases imply the co-existence of multiple stable
states. For example, the tristable phase {E, E/M, M} implies that all three phenotypes – E,
E/M and M can exist in the given range of S1 and S2, i.e. cells can switch back and forth
among these three phenotypes. Depending on the details of EMT induction, cells tend to
follow different trajectories in the phase diagram and thereby undergo different phenotypic
transitions. The tristability of the miR-200/ZEB1 circuit enabled by the CD44s/ZEB1
feedback loop is quite robust to parameter perturbation (Additional file 1: SI Section 4,
Additional file 1: Figure S2).
Next, to investigate the gene expression levels of ZEB1 across E, hybrid E/M and M
cells, we analyze the NCI-60 panel of cell lines that have been classified into E, E/M,
and M phenotypes on a population level based on ensemble CDH1/VIM ratio (Park
et al., 2008). CDH1 encodes the epithelial marker E-cadherin, loss of which is a
hallmark of EMT. VIM encodes vimentin, which is a commonly used marker for the
mesenchymal phenotype. Both ZEB1 and ESRP1 show three different expression levels
across the E, E/M and M cell lines, and the difference among these levels is statistically
significant (Fig. 2c). These results are consistent with the prediction from the TCS model,
which proposes that ZEB1 (Fig. 2a, b) and ESRP1 levels (Additional file 1: Figure S3) in
the hybrid E/M phenotype are different from that of the E phenotype. Further, across the
entire NCI-60 panel, ESRP1 expression negatively correlates with ZEB1 and VIM, and
positively correlates with CDH1 (Jia et al., 2015; Roca et al., 2013; Watanabe et al., 2014).
These observations, together with the reported strong negative correlation between
the expression of ZEB1 and ESRP1 in the lung, breast and pancreatic cancer patient
samples (Preca et al., 2015), suggest that the ZEB1-ESRP1 axis is active across mul-
tiple cancer types (Fig. 2c).
In addition to the expression analysis of ZEB1 from the NCI-60 cell line panel, we
further conducted experiments in three NSCLC cell lines – H820, H1975 and H1299 -
that have been characterized as epithelial, hybrid E/M and mesenchymal respectively
(Schliekelman et al., 2015). Notably, the hybrid E/M H1975 cells stain for both E-cadherin
and vimentin at a single-cell level and display collective migration (Schliekelman et al.,
2015; Jolly et al., 2016). The immunofluorescence staining of the H1975 cells clearly shows
the expression of ZEB1 in the nucleus concomitantly with E-cadherin on the membrane,
which demonstrates that ZEB1 is present in the hybrid E/M phenotype as compared to
the lack of ZEB1 in the epithelial H820 cells (Fig. 2d, Additional file 1: Figure S4).
The intermediate levels of ZEB1 in hybrid H1975 cells are further verified by RT-PCR
(Fig. 2e) and Western blot (Fig. 2f, Additional file 1: Figure S5). Notably, the difference of
SNAIL levels (3 fold) is much smaller compared with the difference of ZEB1 (20 fold)
between epithelial cells - H820 and H1437 and hybrid E/M cells – H1975 (Fig. 2e, f ),
suggesting ZEB1 levels may correspond strongly with maintaining these phenotypes, at
least in these cell lines. Interestingly, the levels of SNAIL in mesenchymal cells – H1299
and H2030 were lower than those in epithelial cells - H820 and H1437 (Fig. 2e, f ), further
arguing for a more critical role of ZEB1 in maintaining a mesenchymal phenotype, poten-
tially via multiple feedback loops (Preca et al., 2015; Gregory et al., 2011).
These results indicate that ZEB1 self-activation (direct or indirect) should be consid-
ered an integral part of the core EMT circuit, thereby implying that TCS model
captures the biological mechanisms more precisely than the CBS one, at least in the
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(Fig. 2a, b) here is quite consistent with that for the miR-200/ZEB1 circuit with direct
ZEB1 self-activation (see Fig. 4 in (31) for comparison). For simplicity, the CD44s/ZEB1
feedback loop is represented by a direct ZEB1 self-activation in the following analysis.
Next, we focus on published experimental data that has been claimed to support the
CBS model over the TCS model. These experimental results are – (a) during TGF-β treat-
ment of MCF10A cells, the concentration of exogenous TGF-β required to increase the
SNAIL abundance is lower than that needed for a comparable increase in ZEB1 abundance
(Zhang et al., 2014), and (b) MCF10A cells that attain a hybrid E/M phenotype revert to
being epithelial upon removal of exogenous TGF-β, but cells that attain a mesenchymal
phenotype fail to do so (Zhang et al., 2014). In the following two sections, we show that
both the CBS and the TCS models can recapitulate these two experimental observations.Different responses of SNAIL and ZEB1 to the EMT-inducing signal- exogenous TGF-β
To test whether the TCS model can recapitulate the different TGF-β-dose responses of
SNAIL and ZEB1, we apply an EMT-inducing signal SA on SNAIL to mimic the induction of
exogenous TGF-β, and analyze the steady-state responses of SNAIL and ZEB1 to different
levels of SA. To investigate how differently SNAIL and ZEB1 respond to TGF-β induction at
a single-cell level compared with that at a cell population level, we design two different kinds
of stochastic simulations. First, at a single-cell level (Fig. 3a), in absence of a detailed under-
standing of the gene expression noise in regulating EMT, we consider the effects of white
noise. Secondly, to investigate population-averaged results (Fig. 3b), we include cell-cell vari-
ability, which is represented by randomly assigned parameters to each cell.
The TCS model results show that the levels of TGF-β (SA) required for the activation
of SNAIL (SA = 20
∗103 molecules) is indeed lower as compared to that for ZEB1
(SA = 40
∗103 molecules) on both the single-cell (Fig. 3a-c) and population levels
(Fig. 3d-f ). The difference in the upregulation of SNAIL and ZEB1 at different
levels of TGF-β might be attributed to the different numbers of binding sites on
3’UTR of mRNA for the corresponding microRNAs – 6 or more binding sites of
miR-200 family on ZEB1 mRNA and 2 binding sites of miR-34 family on SNAIL
mRNA (Kim et al., 2011; Gregory et al., 2008). The different endogenous levels of
miR-34 and miR-200 family members may also affect the difference in ZEB1 and
SNAIL levels. In addition, tristability is more apparent for the ZEB1 mRNA levels
than for the ZEB1 protein levels. Again, this can be attributed to the microRNA-
mediated repression. Therefore, with intermediate levels of ZEB1 mRNA and miR-
200 present in the hybrid E/M phenotype, the ZEB1 protein does not necessarily
reach the intermediate level, because of the strong repression by miR-200; this
results in the relatively less separated E and E/M phenotypes for ZEB1 protein
levels. The fraction of each group with the ZEB1 mRNA levels - low, medium,
high - can be adjusted by the levels of TGF-β (SA) (Additional file 1: Figure S6).
Next, we compare the responses of ZEB1 on the single-cell and population-averaged
levels; we find that ZEB1 mRNA levels display a more significant trimodal distribution
in the single-cell simulation compared with that from the population-averaged result
(Fig. 3c). The cell-to-cell variability, as reflected by parameter randomization, tends to
smoothen the distributions of ZEB1 mRNA in the E and the hybrid E/M phenotypes,
ZEB1 mRNA (molecules)
ZEB1 mRNA (molecules)
µ200
SNAIL
ZEB1
µ34
SA(exogenous TGF- )
Single -cell level
a
Population level
SA (exogenous TGF- )
b
c
d
ZEB1 mRNA (molecules)
e
f
ZEB1 mRNA (molecules)
ZEB1 Protein (10  molecules)   
ZEB1 Protein (10  molecules)
Fig. 3 Simulation of the responses of SNAIL and ZEB1 to EMT-inducing signal SA by the TCS model on single-cell
(a) and population levels (b). For each figure, six different levels of SA are chosen - SA= 0, 20, 36, 49, 64, 90
(∗103 molecules). The distributions of mRNA and protein levels of SNAIL and ZEB in response to different levels of
SA are calculated by Langevin simulation. For (b) and (c), white noise to mimic the fluctuations inside
one cell is considered. For (e) and (f), parameter randomization to mimic the cell-cell variability is included. The
trimodal distribution of ZEB1 mRNA levels when SA = 49
∗103 molecules during EMT is highlighted in
both (c) and (f)
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as compared to that between E/M and M, as reflected by the simulations of single cells
undergoing EMT (Fig. 3a). The difference of ZEB1 mRNA levels in E, E/M and M
phenotypes shown here should not be compared with the gene expression data from
NCI-60 (Fig. 2c), which is not time-course data for individual cells undergoing EMT.
Since the existing experimental data on population measurements only yield average
values, this may help explain why ZEB1 mRNA appears to be bimodally distributed
(Zhang et al., 2014). Consequently, the averaged ZEB1 levels may not be able to argue
strongly in favor of one mathematical model over the other.The inhibition of miR-34 by ZEB1 as well as autocrine TGF- β signaling stabilizes the
mesenchymal phenotype
To decode possible mechanisms of the irreversible nature of the transition from hybrid
E/M to M, we focus on the feedback loop from the miR-200/ZEB1 circuit to the miR-
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effect of this link on the transitions among E, E/M and M, we calculate the bifurcation
diagram of the complete circuit – miR-34/SNAIL/miR-200/ZEB1 - driven by EMT-
inducing signal SA on SNAIL for varying strengths of the inhibition of miR-34 by ZEB1
(Fig. 4b). The stronger the inhibition of miR-34 by ZEB1, the smaller the level of EMT-
inducing signal SA required for the cells to transition into and maintain a M phenotype
(Fig. 4b). In addition, a stronger inhibition of miR-34 by ZEB1 can decrease the
duration of the hybrid E/M phenotype and can therefore promote a quicker transition
from the hybrid E/M phenotype to the M phenotype during temporal dynamic
simulation (Additional file 1: Figure S7).
To characterize the relative stability of E, E/M and M states, we calculate the effective
landscape of EMT at different strengths of the inhibition of miR-34 by ZEB1. Here, the
external activation signal SA is chosen at 50*10
3 molecules, which enables the existence
of all three stable states – E, E/M and M in all cases with different strengths of the
inhibition of miR-34 by ZEB1 (Fig. 4b). When there is no feedback from ZEB1 to miR-
34, cells are mainly bimodally distributed in either the E or the E/M phenotype (left
panel in Fig. 4b). An intermediate strength of the inhibition of miR-34 by ZEB1 enables
all three phenotypes to be attained (middle panel in Fig. 4b). When the strength of the
inhibition of miR-34 by ZEB1 is further increased, the M phenotype becomes the
dominant one, thus cells in this case can maintain the mesenchymal phenotype without
reverting (right panel in Fig. 4b). Therefore, a strong inhibitory feedback from ZEB1 toa
b
Fig. 4 The inhibition of miR-34 by ZEB1 promotes the ‘irreversibility’ of complete EMT, as elucidated by the
TCS model. (a) Bifurcation diagram of ZEB1 mRNA levels in response to the activation signal on SNAIL (SA)
when λZ;μ34 ¼ 0; 0:2; 0:4; 0:6; 0:8; 1. λZ;μ34 is the fold-change parameter which represents the strength
of ZEB1 inhibition on miR-34. λZ;μ34 ¼ 1 represents that there is no inhibition from ZEB1 to miR-34. λZ;μ34
¼ 0 represents strong inhibition from ZEB1 to miR-34. The dotted line in the bifurcation highlights the value
of activation signal SA = 50
∗103 molecules, which is used to calculate the effective landscape (− log(P))as
shown in (b). (b) Effective landscape of EMT for λZ;μ34 ¼ 1 (no feedback), λZ;μ34 ¼ 0:6 (Intermediate feedback)
and λZ;μ34 ¼ 0 (strong feedback). The stable state corresponding to each basin is labeled. The larger the blue
area surrounding a particular state is, the more frequently that stable state can be achieved
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transition from the hybrid E/M to the M phenotype.
Another possible mechanism accounting for the ‘irreversibility’ of the mesenchymal
phenotype can be the autocrine TGF-β/miR-200 loop, as suggested by the CBS model.
Here, we evaluate the effect of the TGF-β/miR-200 loop based on the TCS framework
(Fig. 5a) and show that removal of exogenous TGF-β cannot induce MET but instead
the circuit is able to maintain the mesenchymal phenotype (Phase {M} in Fig. 5b) as
long as the innate production rate of endogenous TGF-β is high. This bifurcation
diagrams (Fig. 5c, d) indicate that the ‘irreversibility’ of mesenchymal phenotype to
switch back to a hybrid E/M phenotype depends directly on the production rate of
endogenous TGF-β.
In summary, both the TCS and the CBS models can explain currently published
experimental results regarding EMT – (a) EMT is a two-step process, from E to E/M
to M. (b) The concentration of exogenous TGF-β required for the activation of SNAIL
is lower than that for ZEB1, (c) The mesenchymal phenotype can be maintained with-
out reverting when exogenous TGF-β is removed due to certain levels of endogenous
TGF-β. In addition, we show that the inhibition of miR-34 by ZEB1 can be responsible
for the irreversibility of a complete EMT. These EMT mathematical models are helpfula b
c d
Fig. 5 The autocrine miR-200/TGF-β loop can maintain the mesenchymal phenotype. (a) The framework of
TCS model with the autocrine miR-200/TGF-β loop. (b) Phase diagram of the circuit shown in (a) in response to
an activation signal on SNAIL (SA) and the production rate of endogenous TGF-β (gmTGF−β ). Two different values
of gmTGF−β are highlighted, as they are the values used to calculate the bifurcation in (c) and (d). (c) Bifurcation of
ZEB1 mRNA levels in response to SA when gmTGF−β ¼ 2 molecules/h. (d) Bifurcation of ZEB1 mRNA level
in response to SA when gmTGF−β ¼ 10 molecules/h. The arrow in (d) highlights that the mesenchymal
state can be maintained without EMT-inducing signal SA when the basal production rate of endogenous TGF-β
is high. Different colors in (b-d) represent different combinations of possible stable states
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newly identified EMT players. To this end, we focus on adding recently identified EMT
regulator – FOXC2, which plays a crucial role in EMT progression, to both the TCS
and the CBS frameworks and test whether these two models can elucidate the function
of FOXC2 in regulating EMT.Overexpression of SNAIL is insufficient to initiate EMT in absence of ZEB1 and FOXC2
The transcription factor FOXC2 serves as a key mediator in regulating EMT and
linking EMT with stem-like properties and with metastatic competence (Mani et al.,
2007; Hollier et al., 2013; Paranjape et al., 2016; Werden et al., 2016). FOXC2 expression
can be upregulated by multiple EMT-inducing signals, such as TGF- β1, Snail, Goosecoid
and Twist. It has been shown that FOXC2 expression is required to maintain the mesen-
chymal phenotype, the invasive properties and the stem cell-enrichment of HMLE cells
following EMT induction (Mani et al., 2007; Hollier et al., 2013).
FOXC2 regulates EMT through its interactions with core EMT components – SNAIL
and ZEB1. Overexpression of SNAIL significantly upregulates the expression of FOXC2
while overexpression of FOXC2 does not affect SNAIL levels (Hollier et al., 2013; Tisza
et al., n.d.) (Additional file 1: Figure S8). This suggests that SNAIL functions as an
upstream regulator of FOXC2. In addition, FOXC2 directly upregulates the expression
of ZEB1 by binding to its promoter region (Werden et al., 2016). Here, we have
expanded both the TCS and CBS models to include transcriptional regulation by
FOXC2 (Fig. 6A, Additional file 1: Figure S9A, see Additional file 1: SI Section 5&6 for
model formulation and Additional file 1: Table S2&3 for parameters).
To analyze the EMT-inducing behaviors of the TCS model in the presence and
absence of FOXC2, we study the effect of two external signals - SA representing an
EMT-inducing signal on SNAIL, and SI representing an inhibitory signal on FOXC2.
The presence of FOXC2 (SI = 0) enables tristability of EMT and accounts for the two-
step transition - from E to E/M and from E/M to M (Fig. 6b, top panel). The absence
of FOXC2 (SI = 2
∗105 molecules) results in low levels of ZEB1 mRNA and consequently
the maintenance of epithelial phenotype (Fig. 6b, bottom panel) irrespective of the high
levels of SNAIL (Additional file 1: Figure S10).
To test the above-mentioned predictions from the TCS model, we examined the
immortalized HMLE cells to assess the role of FOXC2 knockdown (FOXC2-KD) during
EMT. Here we measure the protein levels of canonical EMT markers in the HMLE-
Snail cells, that have already undergone a complete EMT via SNAIL overexpression, in
the presence and absence of FOXC2. We find that FOXC2-KD in HMLE-Snail cells
eliminates the expression of ZEB1, vimentin and fibronectin while it restores the
expression of E-cadherin, thus inducing a complete MET irrespective of SNAIL overex-
pression (Fig. 6c). This experimental observation is consistent with the prediction from
the TCS model, but not with the prediction from the CBS model that an EMT-
inducing signal can still drive the transition from an epithelial state to a hybrid E/M
state upon FOXC2-KD (Additional file 1: Figure S9).
Is it possible that FOXC2 acts together with SNAIL and together can induce
(partial) EMT even without ZEB1? This would argue against TCS and would instead
be consistent with a modified version of CBS. We do not think this is supported by
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effect of FOXC2 on tumor-initiating potential and drug resistance (Paranjape et al.,
2016), traits that are often correlated with EMT (Jolly et al., 2014; Jolly et al., 2015;
Mani et al., 2008; May et al., 2011; Morel et al., 2008). Decreased expression of ZEB1
in PANC-1 cells, which express both epithelial and mesenchymal markers (Gradiz
et al., 2016) and are thus likely to be hybrid E/M cells, results in a complete MET
despite upregulation of SLUG and SNAIL in TGF-β treated cells (Abshire et al.,
2016). Moreover, knockdown of ZEB1, but not necessarily of SNAIL and SLUG, had
pronounced effects in cells losing their EMT-like properties (Weitzenfeld et al., n.d.).
Therefore, we believe that the most consistent interpretation of the data is that
SNAIL (even with FOXC2) is insufficient without ZEB1 and conversely both ZEB1
and FOXC2 are needed (Fig. 6D) and contribute to different aspects of driving EMT
such as repression of epithelial program (ZEB1 is a transcriptional repressor
(Spaderna et al., 2008) and activation of mesenchymal program (FOXC2 is ac d
a b
Fig. 6 Overexpression of SNAIL is not sufficient to initiate EMT in absence of ZEB1 and FOXC2. (a) Integrating
FOXC2 to the TCS framework – TCS-FOXC2. (b) Top panel: Bifurcation diagram of the TCS-FOXC2 circuit when
FOXC2 is present, as reflected by SI = 0. Bottom panel: Bifurcation diagram of the TCS-FOXC2 circuit when
FOXC2 is absent, as reflected by SI = 2
∗105 molecules. (c) Western blot analysis of EMT markers upon SNAIL
overexpression in HMLE cells, and FOXC2 suppression in HMLE–Snail cells respectively. (d) The proposed EMT
regulatory framework integrating transcriptional regulation by FOXC2
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overexpression of ZEB1 in FOXC2 knockdown and overexpression of FOXC2 in
ZEB1 knockdown cells will be crucial in further delineating the mechanisms of EMT
dynamics and distinguishing the principles underlying EMT tristability.Discussion
Phenotypic transitions among epithelial, hybrid E/M, and mesenchymal phenotypes
endow cancer cells with rich plasticity to metastasize and form secondary tumors. To
elucidate the operating principles of EMT/MET, two conceptual frameworks - Ternary
Chimera Switch (TCS) and Cascading Bistable Switches (CBS) - have been proposed.
These models represent different mathematical realizations of the same core EMT
circuit – miR-34/SNAIL/miR-200/ZEB1 – and both highlight that EMT is not an ‘all-
or-none’ response (Jolly et al., 2015; Gupta et al., 2011; Huang et al., 2014; Boareto
et al., 2015), reminiscent of other similar examples of cellular plasticity (Jolly et al.,
2015) in tumor progression.
Here, we discuss the similarities and differences between these two models and
present a new set of experiments that appear to align better with the TCS model. First,
we show that the CD44s/ZEB1 feedback loop can underlie the self-activation of ZEB1.
These results, coupled with the significantly different levels of ZEB1 and ESRP1 across
E, E/M and M phenotypes in the NCI-60 cell line, and the single-cell co-expression of
ZEB1 and E-cadherin in H1975 hybrid E/M cells, reinforce the role of ZEB1 in partial
EMT. Second, we show that the TCS model can recapitulate the experimental
phenomenon that the required concentration of exogenous TGF-β for the activation of
SNAIL is lower than that for the activation of ZEB1, attributing to the stronger inhib-
ition of ZEB1 by miR-200 than the inhibition of SNAIL by miR-34 (Kim et al., 2011;
Gregory et al., 2008). In addition, the TCS modeling results show that the tristability is
more apparent for ZEB1 mRNA than that for ZEB1 protein, which again highlights the
microRNA-mediated regulation. Third, the TCS modeling results suggest that the
inhibition of miR-34 by ZEB1 can stabilize mesenchymal phenotype. Other interactions,
although not exclusively, that can also help maintain mesenchymal phenotype is ZEB1
self-activation (Additional file 1: Figure S11) and the autocrine miR-200/TGF-β loop, as
also pointed out by Zhang et al. (Zhang et al., 2014).
Further experiments that support the TCS model over the CBS model are related to
the knockdown of FOXC2 – a transcription factor that is upregulated by SNAIL and
directly activates the transcription of ZEB1 (Mani et al., 2007; Hollier et al., 2013;
Paranjape et al., 2016; Werden et al., 2016). Our experimental results show that knock-
down of FOXC2 inhibits the gene expression changes concomitant with EMT, including
ZEB1 activation, but does not affect SNAIL levels. According to the CBS model, FOXC2-
KD cells can still undergo a partial EMT because upregulation of SNAIL levels is
independent of FOXC2 and (high SNAIL, low ZEB1) levels are associated with a hybrid
E/M state. But the TCS model proposes that knockdown of FOXC2 aborts EMT com-
pletely in the absence of ZEB1 (and FOXC2) expression irrespective of the high SNAIL
levels, which is consistent with the experimental test. These results are reminiscent of
observations in mouse mammary gland cells that decreased expression of ZEB1/2
is sufficient to re-establish the epithelial features (Das et al., 2009) while
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for ZEB but not necessarily SNAIL in maintaining EMT in certain contexts. Fur-
ther work on the interplay between ZEB1 and FOXC2 will give new insights into
the role of miR-200/ZEB1 circuit during EMT.
The similarities and differences between the two models vis-à-vis the available experi-
mental data calls for further quantitative analysis of EMT regulation in multiple
contexts. The experimental data presented here favor the TCS model, but contextual
differences in regulating EMT (Kalluri & Weinberg, 2009) might enable conditions
where both models can reconcile different experimental observations.
Comparative analysis of these two mechanism-based models suggests several intriguing
testable predictions that can help understand this multi-layered regulation of EMT/MET.
First, ZEB1/2 mRNA, among other EMT regulators, should be measured at a single-cell
level instead of population-averaged level at varying levels of an EMT-inducing signal
such as TGF-β. The reason for this suggestion is three-fold: (a) the cell-to-cell variability
tends to attenuate the observation of the intermediate level of ZEB1/2 mRNA (Fig. 3), (b)
the distribution of ZEB1/2 mRNA levels, as compared with ZEB1/2 protein levels, appears
closer to being trimodal, and (c) although the cell lines belonging to different cancer types
(Park et al., 2008; Schliekelman et al., 2015; Huang et al., 2013) have been classified into E,
E/M, and M based on such ensemble measurements, recent studies have shown that cell
lines can harbor phenotypic heterogeneity, therefore underlining the need to conduct
single-cell studies (Grosse-Wilde et al., 2015). Second, in addition to these dose-response
experiments, time-course measurements of levels of ZEB1/2, SNAIL1/2, miR-200, miR-34
and FOXC2, need to be performed to elucidate temporal dynamics of EMT.
The hybrid E/M state (partial EMT) has gradually drawn attention due to its proposed cru-
cial role in tumor progression and organ fibrosis (Jolly et al., 2015; Lovisa et al., 2016; Nieto
et al., 2016; Lambert et al., 2017). The hybrid E/M state allows collective migration of CTCs
as a cluster and these CTC clusters can evade immune attack (Sarioglu et al., 2015) and often
have much higher metastatic potential than the individually migrating CTCs (Aceto et al.,
2014). The TCS model can be utilized to identify certain ‘phenotypic stability factors’ (PSFs)
(Yaswen, 2014), such as OVOL and GRHL2 (Jolly et al., 2016), which can stabilize a ‘metasta-
ble’ partial EMT phenotype and thus being potential targets to ‘break’ the clusters of CTCs –
the primary ‘bad agents’ of metastasis (Jolly et al., 2015; Aceto et al., 2014). In future, the
landscape approach (Li & Wang, 2014; Li & Wang, 2015) could be utilized to quantify the
stability of the hybrid E/M state and transition processes during EMT and MET. These
insights can move us a step closer to understanding and eventually quantitatively predicting
the population heterogeneity in an isogenic population (Andriani et al., 2016).
In addition, cells undergoing EMT have been shown to acquire tumor-initiating and/or
drug-resistance properties (often together referred to as ‘stemness’ in the context of Cancer
Stem Cells) and to induce cell cycle arrest (Jolly et al., 2015; Mani et al., 2008; Nieto et al.,
2016; Fischer et al., 2015; Zheng et al., 2015). By coupling the TCS model of EMT with the
stemness model – LIN28/let-7/OCT4 in our previous work, we showed that ‘stemness win-
dow’ can slide on the ‘EMT axis’, or in other words, EMT-stemness correspondence can be
fine-tuned by multiple players such as miR-200 that inhibits LIN28, and by PSFs such as
OVOL (Jolly et al., 2015). We also showed that JAG1 – a potential intercellular PSF – can
mediate drug resistance (Boareto et al., 2016). Such a dynamic positioning of the ‘stemness
window’ can reconcile many apparently contradictory experiments about the effect of EMT/
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(Mani et al., 2008; Morel et al., 2008), (b) MET increases stemness (Celià-Terrassa et al.,
2012) and (c) partial EMT possesses maximum stemness (Jolly et al., 2014; Grosse-Wilde
et al., 2015). Future work to integrate the TCS model with regulatory networks for different
‘hallmarks of cancer’(Hanahan & Weinberg, 2011) should be done to extend our under-
standing of EMT mechanisms and anti-metastasis strategies.Conclusions
Our integrative modeling and experimental analyses of EMT/MET core network – miR-34/
SNAIL/miR-200/ZEB1 - help distinguish mechanisms underlying EMT tristability, propose
further experiments to decode the EMT dynamics more explicitly, and serve as a platform
to identify certain ‘underlying basic principles’ pertaining to different hallmarks of cancer.Methods
The model formulation and analyses
The detailed introduction of both the ternary switch (TCS) model and the cascading
bistable switches (CBS) model can be found in the Additional file 1: Section 1&2.
(1)Deterministic analysis
The bifurcation diagrams of the EMT circuits are calculated by the Matcont package
in Matlab. The temporal dynamics of the EMT circuits are calculated by the ode15s
solver in Matlab.
(2)Stochastic simulation
For the single-cell simulation, a Langevin equation is used to describe the dynamic
behaviors of the EMT circuits with the Gaussian white noise and the Euler-Maruyama
method is used to integrate the equation (Kloeden & Platen, 1992).
For population-averaged calculation, 100 sets of parameters for the EMT circuit–
miR-34/SNAIL/miR-200/ZEB1 were generated by parameter randomization (each
parameter except for the hill coefficients is increased or decreased randomly up to 5%
of the original value) to mimic the cell-cell variability. The random sampling follows a
normal distribution. As for the hill coefficient, it follows the normal distribution within
[n − 1, n + 1], where n is the original value.
The effective landscape (Wang et al., 2011; Lu et al., 2014) for the stable state X (E or
E/M or M) is defined by E(X) = − ln(P(X)), where P(X) represents the probability of the
stable state X to be observed.Analysis of gene expression data from NCI-60 cell lines
The expression levels of ESRP1, ZEB1, VIM, CDH1, OVOL2 were downloaded from
Cellminer (Shankavaram et al., 2009) and categorized into E, E/M, and M sets based on
CDH1/VIM ratio (Park et al., 2008). Student’s t-test were used to test the significance
of difference in the expression levels. The Pearson’s correlation coefficient is calculated
between the expression level of ESRP1 and ZEB1, VIM, CDH1, OVOL2 respectively.
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NSCLC cell lines from initial authenticated cell passages, free from mycoplasma, were
grown in RPMI 1640 with 10% FBS and 1% penicillin/streptomycin cocktail. For
immunofluorescence, cells were fixed in 4% paraformaldehyde, permeabilized in 0.2% Tri-
ton X-100, and then incubated overnight with anti-rabbit ZEB1 (1:250; Cat. No.
HPA027524, Sigma Aldrich), anti-rabbit CDH1 (1:200; Cat. No. 3195, Cell Signaling Tech-
nology), anti-rabbit vimentin (1:200; Cat. No. 5741, Cell Signaling Technology), anti-mouse
CDH1 (1:100; Cat. No. 610182, BD Transduction) and anti-mouse vimentin (1:50; Cat. No.
ab8978, Abcam). The primary antibodies were then detected with Alexa conjugated
secondary antibodies (Life technologies). Nuclei were visualized by co-staining with DAPI.RT-PCR analysis of EMT markers in NSCLC cell lines
Total RNA was isolated following manufacturer’s instructions using RNAeasy kit
(Qiagen). cDNA was prepared using iScript gDNA clear cDNA synthesis kit (Bio-Rad).
A TaqMan PCR assay was performed with a 7500 Fast Real-Time PCR System using
TaqMan PCR master mix, commercially available primers, and FAM™-labeled probes
for CDH1, ZEB1, FOXC2 and SNAIL and VIC™-labeled probes for 18S, according to
the manufacturer’s instructions (Life Technologies). Each sample was run in triplicate.
Ct values for each gene were calculated and normalized to Ct values for 18S (ΔCt). The
ΔΔCt values were then calculated by normalization to the ΔCt value for control.Western blot analysis of EMT markers in NSCLC cell lines
Cells were lysed in RIPA lysis assay buffer (Pierce) supplemented with protease and
phosphatase inhibitor. The samples were separated on a 4–15% SDS-polyacrylamide
gel (Biorad). After transfer to PVDF membrane, probing was carried out with primary
antibodies and subsequent secondary antibodies. Primary antibodies were purchased
from the following commercial sources: anti-CDH1 (1:1000; Cell Signaling Technology),
anti-vimentin (1:1000; Cell Signaling Technology), anti-ZEB1 (1:1000; Cell Signaling
Technology), anti-SNAIL (1:1000; Cell Signaling Technology), anti-FOXC2 (1:2000;
Bethyl Laboratories) and anti-GAPDH (1:10,000; Abcam). Membranes were exposed
using the ECL method (GE Healthcare) according to the manufacturer’s instructions.Western blot analysis of EMT markers in HMLE cells
Authenticated immortalized human mammary epithelial (HMLE) cells expressing
empty vector (pWZL), Snail, Snail shControl, or Snail shFOXC2 cells were cultured in
MEGM media as previously described (Werden et al., 2016). For immunoblotting, cells
were lysed in RIPA buffer, run on an 8% gel, and transferred onto nitrocellulose.
Primary antibodies were incubated with the membrane overnight at 4 °C and included
β-actin (Santa Cruz Biotechnology, Dallas, TX, USA), FOXC2 (developed by Dr.
Naoyuki Miura, Hamamatsu University School of Medicine, Hamamatsu, Japan), E-
cadherin (BD Biosciences, San Jose, CA, USA; 61,081), Fibronectin (BD Biosciences;
610,077), Vimentin (V9, Thermo Fisher, MA5–11883), and ZEB1 (Santa Cruz
Biotechnology, Dallas, TX, USA).
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